TRAF6 - Wiki-Pi

Search Results for: TRAF6

Can't find the interaction you're looking for? Try the advanced search

193 interactions involving TRAF6 - TNF receptor associated factor 6 found:

Sort by: Symbol Number of Pathways Number of Drugs Number of Diseases

Symbol	Description	Pathways Hide	Drugs Hide	Diseases Hide
HSPA4	heat shock protein family A (Hsp70) member 4	Regulation of HSF1-mediated heat shock response	Phenethyl Isothiocyanate
IL17RB	interleukin 17 receptor B	Interleukin-17 signaling
IPMK	inositol polyphosphate multikinase	Synthesis of IPs in the nucleus
IQUB	IQ motif and ubiquitin domain containing
IRAK1	interleukin 1 receptor associated kinase 1	PIP3 activates AKT signaling MyD88:MAL(TIRAP) cascade initiated on plasma membrane NOD1/2 Signaling Pathway p75NTR recruits signalling complexes p75NTR recruits signalling complexes NF-kB is activated and signals survival TAK1-dependent IKK and NF-kappa-B activation activated TAK1 mediates p38 MAPK activation JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Transcriptional Regulation by MECP2 Interleukin-1 signaling IRAK1 recruits IKK complex SARS-CoV-2 activates/modulates innate and adaptive immune responses TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation MyD88 dependent cascade initiated on endosome MyD88 cascade initiated on plasma membrane	Fostamatinib
IRAK2	interleukin 1 receptor associated kinase 2	MyD88:MAL(TIRAP) cascade initiated on plasma membrane NOD1/2 Signaling Pathway TAK1-dependent IKK and NF-kappa-B activation activated TAK1 mediates p38 MAPK activation JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 Interleukin-1 signaling IRAK2 mediated activation of TAK1 complex TRAF6-mediated induction of TAK1 complex within TLR4 complex SARS-CoV-1 activates/modulates innate immune responses SARS-CoV-2 activates/modulates innate and adaptive immune responses TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation MyD88 dependent cascade initiated on endosome IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation MyD88 cascade initiated on plasma membrane
IRAK3	interleukin 1 receptor associated kinase 3	MyD88:MAL(TIRAP) cascade initiated on plasma membrane Interleukin-1 signaling	Fostamatinib
IRAK4	interleukin 1 receptor associated kinase 4	PIP3 activates AKT signaling MyD88:MAL(TIRAP) cascade initiated on plasma membrane IRAK4 deficiency (TLR5) IRAK4 deficiency (TLR2/4) PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Interleukin-1 signaling TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation MyD88 dependent cascade initiated on endosome MyD88 cascade initiated on plasma membrane	1-(3-HYDROXYPROPYL)-2-[(3-NITROBENZOYL)AMINO]-1H-BENZIMIDAZOL-5-YL PIVALATE Fostamatinib	Defects of toll-like receptor signaling, including the following disease: Il-1 receptor-associated kinase 4 (IRAK-4) deficiency
IRF5	interferon regulatory factor 5	Interferon gamma signaling Interferon alpha/beta signaling SLC15A4:TASL-dependent IRF5 activation
IRF7	interferon regulatory factor 7	DEx/H-box helicases activate type I IFN and inflammatory cytokines production Interferon gamma signaling TICAM1-dependent activation of IRF3/IRF7 Interferon alpha/beta signaling TRAF3-dependent IRF activation pathway TRAF6 mediated IRF7 activation Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) SARS-CoV-2 activates/modulates innate and adaptive immune responses TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling
IRF8	interferon regulatory factor 8	Interferon gamma signaling Interferon alpha/beta signaling
JAK2	Janus kinase 2	Interleukin-6 signaling Interleukin-6 signaling MAPK3 (ERK1) activation MAPK1 (ERK2) activation Prolactin receptor signaling Prolactin receptor signaling Signaling by SCF-KIT Signaling by Leptin RMTs methylate histone arginines Interleukin-3, Interleukin-5 and GM-CSF signaling Interleukin-3, Interleukin-5 and GM-CSF signaling RAF activation RAF/MAP kinase cascade Interleukin-4 and Interleukin-13 signaling IL-6-type cytokine receptor ligand interactions Signaling by moderate kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Cyclin D associated events in G1 Interferon gamma signaling Regulation of IFNG signaling Regulation of IFNG signaling Interleukin-20 family signaling Interleukin-35 Signalling Signaling by Erythropoietin Signaling by Erythropoietin Interleukin-12 signaling Interleukin-12 signaling Interleukin-23 signaling Interleukin-23 signaling Interleukin-27 signaling Interleukin-27 signaling Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phospholipase C gamma (PLCG) Erythropoietin activates STAT5 Erythropoietin activates RAS Erythropoietin activates RAS Interleukin receptor SHC signaling Signaling downstream of RAS mutants Signaling by RAF1 mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) Potential therapeutics for SARS Inactivation of CSF3 (G-CSF) signaling Inactivation of CSF3 (G-CSF) signaling IFNG signaling activates MAPKs Growth hormone receptor signaling Growth hormone receptor signaling Factors involved in megakaryocyte development and platelet production	2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one XL019 5-phenyl-1H-indazol-3-amine 4-(3-amino-1H-indazol-5-yl)-N-tert-butylbenzenesulfonamide 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]-1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM Ruxolitinib Tofacitinib Pacritinib Baricitinib Entrectinib Fostamatinib Fedratinib Abrocitinib Zanubrutinib Pralsetinib	Polycythemia vera
KCNQ1	potassium voltage-gated channel subfamily Q member 1	Voltage gated Potassium channels Phase 3 - rapid repolarisation Phase 2 - plateau phase	Enflurane Promethazine Miconazole Bepridil Dronedarone Azimilide ICA-105665 Isavuconazole	Short QT syndrome Long QT syndrome, including: Romano-Ward syndrome; Jervell and Lange-Nielsen syndrome (JLNS) Atrial fibrillation Type II diabetes mellitus
LIMD1	LIM domain containing 1	Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha
LNX1	ligand of numb-protein X 1	Antigen processing: Ubiquitination & Proteasome degradation
MALT1	MALT1 paracaspase	Activation of NF-kappaB in B cells Activation of NF-kappaB in B cells Downstream TCR signaling FCERI mediated NF-kB activation FCERI mediated NF-kB activation CLEC7A (Dectin-1) signaling CLEC7A/inflammasome pathway
MAP2K1	mitogen-activated protein kinase kinase 1	MAPK3 (ERK1) activation Frs2-mediated activation Signal transduction by L1 Uptake and function of anthrax toxins RAF activation MAP2K and MAPK activation Negative feedback regulation of MAPK pathway MAP3K8 (TPL2)-dependent MAPK1/3 activation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by MAP2K mutants Signaling by RAF1 mutants	K-252a 5-Bromo-N-[(2S)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide Cobimetinib Bosutinib (5S)-4,5-difluoro-6-[(2-fluoro-4-iodophenyl)imino]-N-(2-hydroxyethoxy)cyclohexa-1,3-diene-1-carboxamide 2-[(2-chloro-4-iodophenyl)amino]-N-{[(2R)-2,3-dihydroxypropyl]oxy}-3,4-difluorobenzamide Mirdametinib N-(5-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-1,3,4-oxadiazol-2-yl)ethane-1,2-diamine 2-[(4-ETHYNYL-2-FLUOROPHENYL)AMINO]-3,4-DIFLUORO-N-(2-HYDROXYETHOXY)BENZAMIDE Trametinib Selumetinib Pimasertib	Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
MAP2K6	mitogen-activated protein kinase kinase 6	NOD1/2 Signaling Pathway Oxidative Stress Induced Senescence activated TAK1 mediates p38 MAPK activation Myogenesis PI5P Regulates TP53 Acetylation Interleukin-1 signaling PKR-mediated signaling	Fostamatinib Pimasertib
MAP2K7	mitogen-activated protein kinase kinase 7	Oxidative Stress Induced Senescence FCERI mediated MAPK activation JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 Uptake and function of anthrax toxins	Pimasertib
MAP3K11	mitogen-activated protein kinase kinase kinase 11	RAF activation Signaling by moderate kinase activity BRAF mutants Paradoxical activation of RAF signaling by kinase inactive BRAF CDC42 GTPase cycle RHOG GTPase cycle RHOV GTPase cycle Signaling downstream of RAS mutants	Fostamatinib

Page 3 out of 10 pages